Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03556332 · ClinicalTrials.gov registry record · Phase 2

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

A Phase 2 study of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
41
Enrollment target
12
Study locations

NCT03556332: Active Phase 2 study of Multiple Myeloma, sponsored by Memorial Sloan Kettering Cancer Center.

NCT03556332 is a Phase 2 study of Multiple Myeloma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 41 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03556332, a Phase 2 study of Multiple Myeloma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
41 participants
Enrollment target
12
Study locations

Study Summary

The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG Lenalidomide
  • DRUG Daratumumab
  • DRUG Carfilzomib
  • PROCEDURE autologous hematopoietic cell transplantation

Study Locations (12)

New York

  • Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
  • Northwell Health - Manhasset
  • New York University - New York
  • Memorial Sloan Kettering Cancer Center - New York
  • Memorial Sloan Kettering Nassau (Limited Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale

Alabama

  • University of Alabama Comprehensive Cancer Center - Birmingham

North Carolina

  • Wake Forest University (Data Collection Only) - Winston-Salem

Wisconsin

  • Medical College of Wisconsin (Data Collection Only) - Milwaukee

Trial Details

FieldValue
Enrollment Target 41 participants
Start Date 2018-07-02
Est. Completion 2026-07
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03556332

The ClinicalTrials.gov registry entry for NCT03556332 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 5 interventions - of which Dexamethasone is the first listed.

NCT03556332 reports 12 study locations spanning 5 distinct geographic areas - top geographies include New York, New Jersey, Alabama.

Frequently Asked Questions

What is clinical trial NCT03556332 about?

NCT03556332 is a clinical study titled "A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation". The purpose of this study is to test any good and bad effects of giving a combination of study drugs before and after autologous stem cell transplant.

What is the current status of trial NCT03556332?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2018-07-02. Estimated completion is 2026-07.

What conditions does trial NCT03556332 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT03556332?

The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Daratumumab (DRUG), Carfilzomib (DRUG), autologous hematopoietic cell transplantation (PROCEDURE).

Who is sponsoring clinical trial NCT03556332?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03556332 being conducted?

This trial has 12 study locations across Alabama, New Jersey, New York, North Carolina, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.